WCPO: After 35 years of surviving HIV and AIDS, Carl Fox is part of a study he believes will find a cure
Fox is part of UC's Trailblazer study
Carl Fox of Northern Kentucky found out he was HIV positive in 1985. After decades of living with the virus and watching the deaths of hundreds of friends, he joined a federally funded study and is allowing WCPO-TV to tell his story.
Carl Fichtenbaum, MD, of the UC Division of Infectious Diseases. Photo/Colleen Kelley/UC Creative + Brand
The TRAILBLAZER study, as it’s called, aims to change the parts of a patient’s white blood cells that HIV latches onto, says Carl Fichtenbaum, MD, professor in the Division of Infectious Diseases at the UC College of Medicine.
Fichtenbaum is a principal investigator on the study and has been Fox’s doctor for years.
“The idea behind this study that we’re doing is to take a person’s cells from their white blood cells that harbor that receptor, take it in the laboratory, remove the receptor through genetic engineering and then infuse those cells back into the person,” he tells WCPO.
“Our hope in the future is that perhaps if we were to do this often enough, and change enough cells in the body, that people who have HIV may be able to control the HIV, even without any medication,” Fichtenbaum says. “And it may be the first steps or ideas to really trying to cure people.”
See the full WCPO study here and read more about the TRAILBLAZER study here.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
An expert pieced together this Roman document like a puzzle
September 1, 2026
National media highlighted a new project by UC Classics Assistant Professor Matthijs Wibier to piece together and translate an ancient Roman text from fragments buried in the desert for more than 1,600 years.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.